Can therapies against cellular aging help treat metabolic diseases?

A growing body of evidence implicates cellular senescence—when cells age and permanently stop dividing—as an important contributor to metabolic dysfunction that can lead to obesity, type 2 diabetes, and metabolic syndrome. A review in the Journal of Internal Medicine explores the research connecting senescent cells to metabolic diseases and highlights the potential of “senotherapeutics” in treatment strategies.

The authors note that senescent cells accumulate in metabolic tissues where they secrete factors that disrupt tissue function by promoting inflammation and fibrosis (or scarring). With this information, investigators have developed senotherapeutic interventions that include senolytics (which eliminate senescent cells), senomorphics (which suppress factors secreted by senescent cells), and senosensitizers (which render senescent cells more vulnerable to clearance).

“By targeting senescent cells, senotherapeutics mitigate one of the root drivers of age- and obesity-related metabolic disease, opening a powerful new frontier in modern medicine,” said corresponding author Allyson Palmer, MD, PhD, of the Mayo Clinic. “This emerging class of therapies could transform how we treat and even prevent metabolic disease.”

URL upon publication: https://onlinelibrary.wiley.com/doi/10.1111/joim.70039

Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com.

About the Journal
The Journal of Internal Medicine is a peer-reviewed scientific journal that publishes original clinical work from bench to bedside covering a broad field of its subspecialties. The journal features original articles, reviews and clinical updates.

About Wiley      
Wiley is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.